Image For Activity Cover
Module 5: Medication for Opioid Use Disorder
Opioid use disorder (OUD) is increasingly encountered in clinical settings, and highly effective FDA approved medications are available for its treatment. This module reviews and compares pharmacological treatment options for individuals with OUD, including methadone, buprenorphine, and naltrexone (oral and long-acting intramuscular formulations). Current evidence for each medication is reviewed in detail and studies comparing each are discussed. The purpose and goal of medications for OUD is also reviewed, including the role of counseling in treatment of OUD and different treatment models. The module includes a discussion of a case vignette in which medication options for OUD are considered.
Target Audience
Physicians, nurses, and healthcare teams who are treating patients with substance use disorder (SUD).
Melissa B. Weimer, DO, MCR | Assistant Professor of Medicine, Yale University

At the conclusion of this activity participants should be able to:

  • Identify the rationale for using medications to treat opioid use disorder
  • Describe effective medications for treating opioid use disorder
  • Explain the unique properties of methadone,buprenorphine, and naltrexone

Core Competencies as a result of participating in this activity:   
Interpersonal Skills and Communication
Medical Knowledge
Patient Care
Method of participation in the activity
In order to receive maximum credit, learners must:

1. Review the materials provided in this module.
2. Earn a minimum cumulative score of 80% on the post-test.
3. Complete an evaluation to assess satisfaction and plans for individual and/or team practice change.
4. Follow instructions at the end of the course regarding how to retrieve a certificate.*

*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.

Funding for this initiative was made possible (in part) by grant nos. 6H79TI081968 and 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

For Buprenorphine Training Inquiries, email PCSS.


Powered By